• 1
    Vogt PK, Bader AG, Kang S. Phosphoinositide 3-kinase: From viral oncoprotein to drug target. Virology 2006; 344: 1318.
  • 2
    Balsara BR, Pei J, Mitsuuchi Y et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 20539.
  • 3
    Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37: 59092.
  • 4
    Okudela K, Hayashi H, Ito T et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: Possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 2004; 164: 91100.
  • 5
    Wang J, Ito T, Udaka N, Okudela K, Yazawa T, Kitamura H. PI3K-AKT pathway mediates growth and survival signals during development of fetal mouse lung. Tissue Cell 2005; 37: 2535.
  • 6
    Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 12214.
  • 7
    Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006; 103: 14759.
  • 8
    Garcia-Rostan G, Costa AM, Pereira-Castro I et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005; 65: 10 199–207.
  • 9
    Davies H, Hunter C, Smith R et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65: 75915.
  • 10
    Massion PP, Kuo WL, Stokoe D et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: Implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002; 62: 363640.
  • 11
    Massion PP, Taflan PM, Shyr Y et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004; 170: 108894.
  • 12
    Travis WD, Brambilla E, Mueller-Hermelink K, Harris CC. Tumor of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press, 2004.
  • 13
    Igarashi H, Yamashita K, Suzuki M et al. Simultaneous imaging of membrane antigen and the corresponding chromosomal locus in pathology archives. Pathol Int 2005; 55: 7536.
  • 14
    Kitayama Y, Igarashi H, Sugimura H. Amplification of FISH signals using intermittent microwave irradiation for analysis of chromosomal instability in gastric cancer. Mol Pathol 1999; 52: 3579.
  • 15
    Kitayama Y, Igarashi H, Kozu T, Nagura K, Ohashi Y, Sugimura H. Repeated fluorescence in situ hybridization by a microwave-enhanced protocol. Pathol Int 2006; 56: 49093.
  • 16
    Cozens AL, Yezzi MJ, Kunzelmann K et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10: 3847.
  • 17
    Yoshii S, Tanaka M, Otsuki Y et al. alphaPIX nucleotide exchange factor is activated by interaction with phosphatidylinositol 3-kinase. Oncogene 1999; 18: 568090.
  • 18
    Sano T, Kitayama Y, Igarashi H et al. Chromosomal numerical abnormalities in early stage lung adenocarcinoma. Pathol Int 2006; 56: 11725.
  • 19
    Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
  • 20
    Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54: 20915.
  • 21
    Li VS, Wong CW, Chan TL et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29.
  • 22
    Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 4559.
  • 23
    Liu Z, Roberts TM. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006; 5: 6757.
  • 24
    Liang X, Lau QC, Salto-Tellez M, Putti TC, Loh M, Sukumar S. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 2006; 5: 5448.
  • 25
    Buttitta F, Felicioni L, Barassi F et al. PIK3CA mutation and histological type in breast carcinoma: High frequency of mutations in lobular carcinoma. J Pathol 2006; 208: 35055.
  • 26
    Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006; 1: 62934.
  • 27
    Sasaki H, Endo K, Takada M et al. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer 2006; 54: 1038.
  • 28
    Sasaki H, Kawano O, Endo K et al. Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 2006; 133: 2036.